Compare Tidewater Inc (TDW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs TG Therapeutics Inc — how do they compare? Tidewater Inc trades at $77.7 (market cap $3.75B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 2.2× Tidewater Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals.
| TDW | TGTX | |
|---|---|---|
Market Cap | $3.75B | $8.26B |
Sector | Utilities | Health |
52-Week High | $91.12 | $59.06 |
52-Week Low | $47.29 | $26.39 |
Enterprise Value | $3.85B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $75.43, down 0.51% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent earnings show mixed results, missing Q1 2026 estimates with $0.12 EPS versus $0.75 expected. The company maintains strong profitability with a 22.16% net margin and 24.03% ROE, while valuation ratios like a P/E of 12.72 suggest potential undervaluation. News highlights include the acquisition of Tidewater Logistics by FTAI Infrastructure in June 2026.
The outlook is cautiously optimistic due to solid fundamentals and analyst buy ratings, but risks include earnings volatility and sector sensitivity. Upside potential hinges on execution improvements, while downside risks stem from energy market fluctuations and competitive pressures.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
